1. Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer 
Rahul Aggarwal, Xiao Wei, Won Kim, Eric J. Small, Charles J. Ryan, Peter Carroll, Matthew Cooperberg, Michael J. Evans, Thomas Hope 
European Urology Oncology 
Volume 1, Issue 1, Pages (May 2018)
DOI: /j.euo
Copyright © 2018 European Association of Urology Terms and Conditions

2. Fig. 1
Changes in PSMA uptake on PET from baseline by metastatic lesion. Maximum-intensity projection images from baseline 68Ga-PSMA-11 PET scans for each patient with (A) metastatic castration-sensitive prostate cancer and (B) metastatic castration-resistant prostate cancer. Up to seven metastatic lesions in bone and soft tissue were chosen for analysis. The change in SUVmax per lesion is shown below the image for each patient following treatment initiation with (A) androgen deprivation therapy (ADT) and (B) enzalutamide. Marks along the x-axis represent PSMA PET time points. ADT=androgen deprivation therapy; enz=enzalutamide; PET=positron emission tomography; PSMA=prostate-specific membrane antigen; SUV=standardized uptake value; W2=week 2; W4=week 4.
European Urology Oncology 2018 1, 78-82DOI: ( /j.euo )
Copyright © 2018 European Association of Urology Terms and Conditions